Frequently Asked Questions
What is SiO2 Materials Science?
SiO2 Materials Science (SiO2) is a privately-owned, Auburn, Alabama-based advanced materials science company. We invented a breakthrough, patented, hybrid material which brings the best qualities of glass and plastic without the drawbacks of either. Our technology for primary packaging is used by pharmaceutical, genomics, diagnostics, health, and beauty companies to help bring their innovations to life. Our most common products include high-performance, durable vials, syringes, blood collection tubes, and cartridges for auto-injectors and wearable devices.
Where is SiO2 manufacturing located?
SiO2 is a U.S. company. Our corporate offices, research laboratories, and manufacturing facilities are based in Auburn, Alabama.
What is SiO2’s history in advanced materials manufacturing?
SiO2 has nearly 60-years of advanced packaging materials innovation in both the life science and consumer goods markets. Beginning in the 1970s, we invented a range of FDA-approved medical products for storing samples and packaging medicines. Our most recent innovations include cryogenic vials, high-performance syringes, and specialty blood collection tubes.
What are the benefits of SiO2’s technology?
SiO2’s patented barrier technology combines the benefits of glass and plastic, without any of their drawbacks. This glass-like coating, which is applied to our polymer containers, provides a highly effective barrier to environmental gases, moisture, and particles. There are no metal ions, no particles, no leachables, and no oils. Our technology creates a completely inert container. The advantages of SiO2’s primary containers are: Thermal Stability & Integrity, Inert, Chemical Stability, Gas Barrier, Mechanical Durability, No Breakage, and Precision Molding.
Is SiO2’s coating material safe for use with vaccines?
Yes. SiO2’s primary containers can pair with a wide range of drugs and are designed to store, transport, and protect highly sensitive biological drugs and vaccines and therapies, including the mRNA, cell, and gene therapy solutions being developed in response to the COVID-19 pandemic.